Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00515-6/fulltext?dgcid=hubspot_email_conferencealerts_esmo23&utm_campaign=conferencealerts&utm_medium=email&_hsmi=278989396&_hsenc=p2ANqtz-86XhOP4dNMwfph1KDsAdxodmss8ei3fOSpDksvVexTBBfroshpB39GaACGRhyJ4WcPL2AUXrTA6Pq-j6y3QwsjjBkWbw&utm_content=278989396&utm_source=hs_email